H. G. Grigoleit

Comparison of Drug Elimination by Current Methods of Blood Purification

Drug elimination by extracorporeal methods (hemodialysis, hemoperfusion, hemofiltration, plasmapheresis) was investigated in an ex vivo model using banked blood. The drugs (cefotaxime, glibenclamide,

Treatment of uremic bone disease action of 5,6-trans-25-hydroxycholecalciferol (a vitamin D-analog) in chronic renal failure

SummaryInvestigations were performed in order to test the biological effectiveness of 5,6-trans-25-hydroxycholecalciferol in patients suffering from terminal renal failure. All patients received for six days a daily i.v. injection of 100 U of this compound: The absorption of47calcium increased in four of five patients, the serum calcium level rose in all. The data suggest that 5,6-trans-25-hydroxycholecalciferol may be useful in the treatment of uremic bone disease, especially because this compound has little, if any, activity in stimulating the mobilization of calcium from the bone.ZusammenfassungDie biologische Aktivität von 5,6-trans-25-Hydroxycholecalciferol wurde bei Patienten mit terminaler Niereninsuffizienz untersucht. Alle Patienten erhielten über einen Zeitraum von 6 Tagen täglich 100 U dieser Substanz intravenös. Nach dieser Therapie fand sich ein Anstieg der Absorption von47Calcium bei 4 Patienten sowie bei allen ein Anstieg des Serumcalciums. Die Ergebnisse lassen hoffen, daß 5,6-trans-25-Hydroxycholecalciferol schon in niedriger Dosierung eine nützliche Therapie der urämischen Osteopathie sein könnte, um so mehr, als diese Substanz kein Calcium aus dem Knochen mobilisiert.

The metabolism and organ distribution of 5,6-trans-25-hydroxycholecalciferol, an analog of vitamin D3 in vitamin D-deficient rats

SummaryInvestigations have been performed on the metabolism and organ distribution of 5,6-trans-25(OH)D3, which represents an analog of vitamin D3 being active in uremia. This analog is rapidly metabolized into at least two more metabolites. The main storage organ for this compound seems to be fat, whereas liver and intestinal mucosa showed at 24 hrs the highest concentration of polar metabolites. In contrast to 25(OH)D3 5,6-trans-25 (OH)D3 is much less absorbed from the intestinal tract, which should be considered if this compound is applied for treatment of uremic bone diseases.